In one of these studies, a positive response of NSCLC patients to anti-PD-1/PD-L1 therapy was correlated to an increased intratumoral density of CD8+ CD103+ TILs, which displayed typical transcriptomic and phenotypic profiles of TRM (83). The gene discussed is CD8A; the disease is non-small cell lung carcinoma.